Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enovis (GB:0I1B)
LSE:0I1B
Holding GB:0I1B?
Track your performance easily
0I1B Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$38.55 - $64.85
Previous Close$41.42
Volume2.00
Average Volume (3M)48.21K
Market Cap
$2.29B
Enterprise Value$3.61B
Total Cash (Recent Filing)$35.00M
Total Debt (Recent Filing)$1.34B
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Nov 06, 2024EPS Estimate
$0.62Last Dividend Ex-Date
Apr 05, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding55,850,500
10 Day Avg. Volume38,625
30 Day Avg. Volume48,207
Standard Deviation0.14
R-Squared0.22
Alpha-0.00404
Financial Highlights & Ratios
Price to Book (P/B)0.69
Price to Sales (P/S)1.20
Price to Cash Flow (P/CF)73.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.88
Enterprise Value/Gross Profit3.64
Enterprise Value/Ebitda20.75
Forecast
1Y Price Target
$64.14Price Target Upside54.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Enovis News
Bulls Say, Bears Say
Bulls Say
Integration And Product LaunchENOV is making progress on the integration and setting up its portfolio and commercial channel to go on the offensive once dissynergies moderate, with important products set to launch.
Strategic Growth And Market ExpansionManagement has continued to improve the highly-profitable Prevention & Recovery base while expanding into higher-margin and growth recon franchises, positioning the company for additional share gain, scale, and leverage.
Valuation And Market PositionENOV is undervalued compared to its mid-cap and ortho peers and warrants a higher P/E multiple given the top- and bottom-line catalysts ahead.
Bears Say
Competitive ConcernsSlower growth in the second quarter won't help address growing competitive concerns regarding ENOV's U.S. shoulder business, as well as the hip and knee segments.
Financial PerformanceSales were flat in the Americas, with growth in Canada being offset by soft performance in the U.S., partly due to the continued impact of the Change Healthcare cyberattack.
Investor SentimentLack of upside compared to conservative guidance and slowing U.S. pro-forma growth is keeping a lid on investor sentiment.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.38% Insiders
40.91% Mutual Funds
2.41% Other Institutional Investors
32.48% Public Companies and
Individual Investors
0I1B FAQ
What was Enovis’s price range in the past 12 months?
Enovis lowest share price was $38.55 and its highest was $64.85 in the past 12 months.
What is Enovis’s market cap?
Currently, no data Available
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is Nov 06, 2024 which is in 18 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on Aug 07, 2024. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.593 by $0.027.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis pays a Notavailable dividend of $16.67 which represents an annual dividend yield of N/A. See more information on Enovis dividends here
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is $0.62.
How many shares outstanding does Enovis have?
Enovis has 55,850,500 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of $0.62 in its last earnings report, beating expectations of $0.593. Following the earnings report the stock price went down -1.787%.
Which hedge fund is a major shareholder of Enovis?
Among the largest hedge funds holding Enovis’s share is Diamond Hill Capital Management Inc. It holds Enovis’s shares valued at 126M.
---
Enovis Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.14 (54.85% Upside)
$64.14 (54.85% Upside)
Blogger Sentiment
Bullish
GB:0I1B Sentiment 100%
Sector Average 68%
Sector Average 68%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.91%
12-Months-Change
Fundamentals
Return on Equity
-3.18%
Trailing 12-Months
Asset Growth
22.47%
Trailing 12-Months
Company Description
Enovis
Colfax Corp. operates as a diversified technology company that provides orthopedic care and fabrication technology products and services to customers. The firm operates its business through the following segments: Medical Technology; and Fabrication Technology. The Medical Technology segment develops, manufactures and distributes medical devices with a broad range of products used for rehabilitation, pain management and physical therapy. The Fabrication Technology develops, manufactures, and supplies consumable products and equipment. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Annapolis Junction, MD.
---
0I1B Company Deck
---
0I1B Earnings Call
Q2 2024
0:00 / 0:00
---
0I1B Stock 12 Month Forecast
Average Price Target
$64.14
▲(54.85% Upside)
Technical Analysis
Best Analysts Covering 0I1B
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
+0.56%
reiterated a buy rating 19 days ago
Copying Vijay Kumar's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +0.56% per trade.
---